A detailed history of Hudson Bay Capital Management LP transactions in Arcus Biosciences, Inc. stock. As of the latest transaction made, Hudson Bay Capital Management LP holds 175,000 shares of RCUS stock, worth $2.56 Million. This represents 0.01% of its overall portfolio holdings.

Number of Shares
175,000
Previous 160,000 9.38%
Holding current value
$2.56 Million
Previous $2.44 Million 9.81%
% of portfolio
0.01%
Previous 0.01%

Shares

14 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 13, 2024

BUY
$13.69 - $18.01 $205,350 - $270,150
15,000 Added 9.38%
175,000 $2.68 Million
Q2 2024

Aug 14, 2024

SELL
$14.59 - $18.48 $72,950 - $92,400
-5,000 Reduced 3.03%
160,000 $2.44 Million
Q1 2024

May 15, 2024

SELL
$14.83 - $20.18 $74,150 - $100,900
-5,000 Reduced 2.94%
165,000 $3.12 Million
Q4 2023

Feb 14, 2024

BUY
$13.43 - $19.63 $1.21 Million - $1.77 Million
90,000 Added 112.5%
170,000 $3.25 Million
Q3 2023

Nov 14, 2023

SELL
$17.62 - $23.54 $616,700 - $823,900
-35,000 Reduced 30.43%
80,000 $1.44 Million
Q2 2023

Aug 14, 2023

BUY
$16.97 - $22.03 $3,394 - $4,406
200 Added 0.17%
115,000 $2.34 Million
Q1 2023

May 15, 2023

BUY
$15.96 - $23.15 $1.03 Million - $1.5 Million
64,800 Added 129.6%
114,800 $2.09 Million
Q4 2022

Feb 14, 2023

BUY
$19.7 - $35.71 $492,500 - $892,750
25,000 Added 100.0%
50,000 $1.03 Million
Q3 2022

Nov 14, 2022

SELL
$23.23 - $30.07 $139,380 - $180,420
-6,000 Reduced 19.35%
25,000 $654,000
Q2 2022

Aug 12, 2022

BUY
$17.23 - $37.73 $361,830 - $792,329
21,000 Added 210.0%
31,000 $786,000
Q1 2022

May 16, 2022

BUY
$28.92 - $41.83 $289,200 - $418,300
10,000 New
10,000 $316,000
Q4 2020

Feb 12, 2021

SELL
$17.0 - $32.36 $1.45 Million - $2.75 Million
-85,000 Closed
0 $0
Q3 2020

Nov 12, 2020

SELL
$17.14 - $25.47 $428,500 - $636,750
-25,000 Reduced 22.73%
85,000 $1.46 Million
Q2 2020

Aug 12, 2020

BUY
$13.97 - $36.56 $1.54 Million - $4.02 Million
110,000 New
110,000 $2.72 Million

Others Institutions Holding RCUS

About Arcus Biosciences, Inc.


  • Ticker RCUS
  • Exchange NYSE
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 72,160,000
  • Market Cap $1.05B
  • Description
  • Arcus Biosciences, Inc., a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. Its product pipeline includes, Etrumadenant, a dual A2a/A2b adenosine receptor antagonist, which is in a Phase 1b/2 clinical trial; and Zimberelimab, an anti-PD-1 antibody that is in Phase 1b clinical trial for ...
More about RCUS
Track This Portfolio

Track Hudson Bay Capital Management LP Portfolio

Follow Hudson Bay Capital Management LP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Hudson Bay Capital Management LP, based on Form 13F filings with the SEC.

News

Stay updated on Hudson Bay Capital Management LP with notifications on news.